Cancer Research Institute
Clinical Trials
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer
This study is currently enrolling.
The purpose of this study is to test the safety and early signs of efficacy of an experimental drug called ELVN-002 for the treatment of solid tumors carrying HER2 genetic alterations, in particular NSCLC and breast cancer. ...
A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer
This study is currently enrolling.
Participants will be invited to take part in this clinical research study if they have been treated for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 negative (HER2)-negative breast cancer and have ...
A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and
Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer
Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer
This study is currently enrolling.
The purpose of this research is to test the safety of an investigational drug called BMS-986442 administered in combination with nivolumab, or in combination with nivolumab and chemotherapies (see Study Treatments section). Thi ...
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Cancer With FGFR2b Overexpression
This study is currently enrolling.
You are being asked to take part in Part 2 of this study because you have advanced gastric cancer (a disease in which cancer cells form in the lining of the stomach) or gastroesophageal junction cancer (a type of cancer forming ...
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In
Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade
Serous Ovarian Cancer (LGSOC).
Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade
Serous Ovarian Cancer (LGSOC).
This study is currently enrolling.
The main aims of this clinical study are to: (a) Find out if the best course of study treatment is to take either VS-6766 alone (monotherapy) or to take VS-6766 together (in combination) with defactinib; (b) Understand the safe ...
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
This study is currently enrolling.
The investigational anti-cancer drugs being studied are called amivantamab (JNJ-61186372) and lazertinib (JNJ-73841937). They are being developed for the treatment of locally advanced or metastatic (i.e., spread outside your lu ...
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen
This study is currently enrolling.
A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis with an Inadequate Response to Conventional Therapy
This study is currently enrolling.
You are being asked to take part in this study because you have been diagnosed with or have symptoms of moderately to severely active ulcerative colitis (UC). UC is a chronic inflammatory disorder of the bowels. People with UC ...
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
This study is currently enrolling.
A study comparing VRd followed by ciltacabtagene autoleucel, versus VRd followed by Rd Therapy in Subjects with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy ...